AVN 66.81 Increased By ▲ 1.96 (3.02%)
BOP 8.80 Increased By ▲ 0.10 (1.15%)
CHCC 126.82 Increased By ▲ 2.61 (2.1%)
DCL 9.07 Increased By ▲ 0.17 (1.91%)
DGKC 102.25 Increased By ▲ 1.36 (1.35%)
EFERT 61.57 Decreased By ▼ -0.03 (-0.05%)
EPCL 44.60 Increased By ▲ 1.60 (3.72%)
FCCL 20.65 Increased By ▲ 0.25 (1.23%)
FFL 14.20 Increased By ▲ 0.38 (2.75%)
HASCOL 14.03 Increased By ▲ 0.46 (3.39%)
HBL 129.70 Increased By ▲ 0.88 (0.68%)
HUBC 79.25 Increased By ▲ 0.75 (0.96%)
HUMNL 6.42 Decreased By ▼ -0.08 (-1.23%)
JSCL 23.16 Increased By ▲ 0.86 (3.86%)
KAPCO 28.11 Increased By ▲ 0.48 (1.74%)
KEL 3.71 Increased By ▲ 0.10 (2.77%)
LOTCHEM 12.66 Increased By ▲ 0.19 (1.52%)
MLCF 37.22 Increased By ▲ 0.70 (1.92%)
OGDC 103.20 Increased By ▲ 5.66 (5.8%)
PAEL 31.96 Increased By ▲ 1.11 (3.6%)
PIBTL 12.12 Increased By ▲ 0.25 (2.11%)
PIOC 86.50 Increased By ▲ 3.00 (3.59%)
POWER 9.23 Increased By ▲ 0.06 (0.65%)
PPL 93.70 Increased By ▲ 5.78 (6.57%)
PSO 195.12 Increased By ▲ 4.84 (2.54%)
SNGP 43.20 Increased By ▲ 0.46 (1.08%)
STPL 13.39 Increased By ▲ 0.14 (1.06%)
TRG 57.28 Increased By ▲ 4.38 (8.28%)
UNITY 23.35 Decreased By ▼ -0.27 (-1.14%)
WTL 1.01 No Change ▼ 0.00 (0%)
BR100 4,245 Increased By ▲ 50.8 (1.21%)
BR30 21,373 Increased By ▲ 284.43 (1.35%)
KSE100 40,900 Increased By ▲ 522.34 (1.29%)
KSE30 17,262 Increased By ▲ 245.59 (1.44%)

FRANKFURT: Bayer will apply for approval to make its blockbuster blood thinner Xarelto available for treating children, the German company said on Monday, after a study showed strong efficacy and safety in children with thromboembolism.

The results of the phase III study were similar to those seen in previous studies with adults, the German company said in a statement.

Bayer added that it would submit an application to the European Medicines Agency for an extension of the Xarelto marketing authorisation. It did not give a timeframe.

Xarelto is Bayer's best-selling drug and contributed 3.6 billion euros ($4.04 billion) in revenue to the group's pharmaceutical business last year.

Bayer jointly developed Xarelto with Johnson & Johnson's Janssen Pharmaceuticals, which sells the blood clot preventer under a licensing agreement in the United States.

J&J reported 2018 Xarelto sales of $2.47 billion.

Copyright Reuters, 2019